This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions
Generated Narrative: Group 236776
version: 74; Last updated: 2025-03-20 18:40:09+0000
Profile: ConceptualExposureDefinition
Artifact Author: Computable Publishing®: MAGIC-to-FEvIR Converter:
RelatesTo
- type: part-of
- targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)
url: https://fevir.net/resources/Group/236776
identifier: FEvIR Object Identifier/https://fevir.net/FOI/236776, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-comparator-85394-C-85798
name: Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85394_C_85798
title: ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
description:
This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.
Code | Value[x] |
Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | ConceptualExposureDefinition |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
membership: Conceptual